Noll L. Campbell
Faculty Associate, Center on Center on Aging and Life Course
2004 Geriatric Specialty Residency, University of North Carolina Hospitals
2003 Pharmacy Practice Residency, St. Vincent Hospital and Health Services
2002 PharmD, Butler University
As an investigator with the Regenstrief Institute and the Indiana University Center for Aging Research, Dr. Campbell’s research focuses on both acute and chronic adverse cognitive effects of medications, including research related to delirium and dementia. He also conducts research on barriers and interventions for medication adherence among older adults with or at risk of cognitive impairment. He has conducted pharmacoepidemiologic and qualitative research, as well as randomized controlled trials. Dr. Campbell has received support for his research from the National Institutes of Health, Astellas, and Merck and Co.
Service and Engagement
PHRM 495: Independent Study
PHRM 845: Integrated Pharmacotherapy III
Honors and Credentials
2015 Invited Attendee, Charleston Conference for Alzheimer’s Disease
Hulman Award for Achievement in Geriatrics
Merck/AGS New Investigator Award
1. Khan BA, Perkins AJ, Gao S, Hui SL, Campbell NL, Farber MO, Chlan L, Ely EW, Boustani MA. The CAM-ICU-7 Delirium Severity Scale: A Novel Delirium Severity Instrument in the Intensive Care. Crit Care Med. 2017 May;45(5):851-857.
2. Campbell NL, Perkins AP, Gao S, Skaar TC, Li L, Hendrie HC, Fowler N, Callahan CM, Boustani MA. Adherence and tolerability of Alzheimer’s disease medications: a pragmatic randomized trial. J Am Geriatri Soc 2017;65(7):1497-1504.
3. Wang S, Allen D, Kheir YN, Campbell NL, Khan B. Aging and Post-Intensive Care Syndrome (PICS): A Critical Need for Geriatric Psychiatry. Am J Geriatr Pyschiatry 2017, In Press
4. Campbell NL, Unverzagt F, Lamantia MA, Khan BA, Boustani MA. Risk factors for progression of early cognitive impairment to dementia. Clin Geri Med.2013. 29 (4), 873-893.
5. Campbell NL, Zhan J, Tu W, Weber Z, Ambeuhl R, McKay C, McElwee N. Self-Reported Medication Adherence Barriers among Ambulatory Older Adults with Mild Cognitive Impairment. Pharmacotherapy. 2016;36(2):196-202.
6. Campbell NL, Perkins AJ, Bradt P, Perk S, Wielage R, Boustani M, Ng D. The association of anticholinergic burden with cognitive impairment and healthcare utilization. Pharmacotherapy 2016;36(11):1123-1131.
7. Wang C, Gao S, Hendrie HC, Kesterson J, Campbell NL, Shekhar A, Callahan CM. Antidepressant Use in the Elderly is Associated with an Increased Risk of Dementia. Alzheimer Dis Assoc Disord 2016; 30(2):99-104.
8. AGS/NIA Delirium Conference Writing Group, Planning Committee and Faculty. The American Geriatrics Society/National Institute on Aging Bedside-to-Bench Conference: Research Agenda on Delirium in Older Adults. J Am Geriatr Soc 2015; doi: 10.1111/jgs.13406.
9. Campbell NL, Boustani MA. Adverse Cognitive Effects of Medications: Turning Attention to Reversibility. JAMA Intern Med 2015; 175(3): 408-409.
10. Campbell NL, Skaar T, Perkins AJ, Gao S, Li L, Khan BA, Boustani MA. Characterization of Hepatic Enzyme Activity in Older Adults with Dementia: Potential Impact on Personalizing Pharmacotherapy. Clin Interv Aging 2015; 10:269-275.